Menstrual Migraine and Treatment Options: Review
- PMID: 27910087
- DOI: 10.1111/head.12978
Menstrual Migraine and Treatment Options: Review
Abstract
Objective: A review of treatment options for menstrual migraine.
Background: Migraine affects ∼30 million people in the US. A subset of female migraineurs have migraines that are mainly associated with menstruation. Menstrual migraine (MM) is divided into pure MM and menstrually related migraine. Pure MM attacks occur only with menstruation and have a prevalence of 1%. Menstrually related migraine has a prevalence of 6-7%, and occurs both during menstruation as well as during the rest of the cycle. MM is usually without aura and is more severe, longer lasting, and more resistant to treatment due to the effects of ovarian hormones, specifically estrogen. MM treatment is divided into acute, short-term prophylaxis, and daily prevention. The best-studied acute treatments are triptans. For short-term prophylaxis, triptans, non-triptans, or combinations are used. Some preventive medications may be used daily to prevent MM. Many anti-epileptic medications used in migraine prevention can affect the efficacy of oral contraceptives and hormonal treatments, so caution is indicated when these are used.
Methods: PubMed, Scopus, Cochrane, and Embase were searched for MM and treatments.
Results: Many randomized, placebo-controlled, prospective studies have evaluated the efficacy of sumatriptan, rizatriptan, naratriptan, zolmitriptan, and almotriptan in MM. Reviewing numerous studies with statistically significant results, rizatriptan has the best overall evidence for acute treatment of MM, ranging from pain-free responses of 33-73% at 2 hours. Sumatriptan and rizatriptan have shown similar efficacies of 61-63% in terms of 2 hour pain freedom. Rizatriptan showed sustained pain relief between 2 and 24 hours with an efficacy of 63% and sustained pain freedom for MM between 2 and 24 hours with an efficacy of 32%. For short-term prevention of MM, there were four randomized controlled trials for frovatriptan taken twice daily, one trial for zolmitriptan taken three times daily, and two studies for naratriptan taken twice daily, all of which showed statistically significant results. Among studies on non-triptans for short-term prevention of MM, magnesium, estrogen, naproxen sodium, and dihydroergotamine all had statistically significant results. Many antiepileptic medications taken for prevention of MM can cause enzyme induction affecting oral contraceptives (OCs) and hormonal treatments to different degrees. Topiramate has the least effect on OCs at doses below 200 mg/day. Lamotrigine noticeably decreases oral contraceptive levels; however, the evidence for it as a preventive medication is not strong.
Conclusion: MM can be very difficult to treat. For acute treatments, rizatriptan has the best overall evidence. For short-term prevention, frovatriptan, zolmitriptan, or naratriptan, as well as magnesium, estrogen, naproxen sodium, or dihydroergotamine may be useful.
Keywords: estrogen; hormones; menstrual migraine; menstrually related migraine; prophylaxis.
© 2016 American Headache Society.
Comment in
-
Menstrual Migraine and Treatment Options: Review.Headache. 2018 Jan;58(1):145-146. doi: 10.1111/head.13203. Headache. 2018. PMID: 29292510 No abstract available.
-
Menstrual Migraine and Treatment Options-A Response.Headache. 2018 Jan;58(1):147. doi: 10.1111/head.13224. Headache. 2018. PMID: 29292511 No abstract available.
Similar articles
-
Menstrual migraine: an updated review on hormonal causes, prophylaxis and treatment.Expert Opin Pharmacother. 2014 Oct;15(14):2063-70. doi: 10.1517/14656566.2014.947959. Epub 2014 Aug 6. Expert Opin Pharmacother. 2014. PMID: 25100506 Review.
-
Rizatriptan: an update of its use in the management of migraine.Drugs. 2002;62(10):1539-74. doi: 10.2165/00003495-200262100-00007. Drugs. 2002. PMID: 12093318 Review.
-
Spotlight on rizatriptan in migraine.CNS Drugs. 2002;16(10):715-20. doi: 10.2165/00023210-200216100-00005. CNS Drugs. 2002. PMID: 12269863 Review.
-
Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis.Cephalalgia. 2014 Apr;34(4):258-67. doi: 10.1177/0333102413508661. Epub 2013 Oct 9. Cephalalgia. 2014. PMID: 24108308
-
Rational migraine management: optimising treatment with the triptans.Funct Neurol. 2000;15 Suppl 3:182-91. Funct Neurol. 2000. PMID: 11200789 Review.
Cited by
-
Exploring the effects of resveratrol supplementation on cerebrovascular function in hormonal migraineurs: A pilot study.IBRO Neurosci Rep. 2023 Oct 18;15:310-319. doi: 10.1016/j.ibneur.2023.10.005. eCollection 2023 Dec. IBRO Neurosci Rep. 2023. PMID: 38204576 Free PMC article.
-
Considerations for hormonal therapy in migraine patients: a critical review of current practice.Expert Rev Neurother. 2023 Dec 19;24(1):1-21. doi: 10.1080/14737175.2023.2296610. Online ahead of print. Expert Rev Neurother. 2023. PMID: 38112066 Free PMC article. Review.
-
Comparative efficacy of different treatments for menstrual migraine: a systematic review and network meta-analysis.J Headache Pain. 2023 Jul 3;24(1):81. doi: 10.1186/s10194-023-01625-x. J Headache Pain. 2023. PMID: 37400775 Free PMC article. Review.
-
Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders.J Headache Pain. 2023 Mar 16;24(1):26. doi: 10.1186/s10194-023-01560-x. J Headache Pain. 2023. PMID: 36927366 Free PMC article.
-
Acupuncture for menstruation-related migraine prophylaxis: A multicenter randomized controlled trial.Front Neurosci. 2022 Aug 26;16:992577. doi: 10.3389/fnins.2022.992577. eCollection 2022. Front Neurosci. 2022. PMID: 36090267 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous